GlassScriptPhysician profile
Walter John Passarello
NPI 1376536847
$1,373.66
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $240 · 2022: $12.94 · 2023: $12.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $229.13 | 2019-2020 | |
| Pfizer INC. | $174.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $142.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $108.54 | 2019 | |
| Abbvie INC. | $98.93 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $92.58 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.35 | 2019 | |
| Amarin Pharma, INC. | $69.44 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.99 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $41.00 | 2019 | |
| Novo Nordisk INC | $39.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.44 | 2019 | |
| Ironshore Pharmaceuticals INC. | $27.24 | 2019 | |
| Dermira, INC. | $22.61 | 2019 | |
| Allergan, INC. | $21.15 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.95 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.06 | 2019 | |
| Genentech USA, INC. | $14.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.73 | 2020 | |
| Nabriva Therapeutics, Plc | $12.83 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.69 | 2019 | |
| Ibsa Pharma INC. | $11.20 | 2019 | |
| Glaxosmithkline, LLC. | $10.87 | 2019 | |
| Fidia Pharma USA INC. | $8.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Passarello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.